Roze et al[43] investigated potential target-able genomic alterations by whole genome sequencing on 46 tumor samples and matched normal DNA, found higher mutational burden in recurrent tumors, and identified tumor protein p53 (TP53) mutations in 3 patients (3/33; 9.1%) with higher mitotic activity. This evidence concerns the gene TP53 and neoplasm.